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ABSTRACT:
ABL2 (also known as ARG (ABL related gene)) is closely related to the well-studied Abelson kinase cABL. ABL2 is involved in
human neoplastic diseases and is deregulated in solid tumors. Oncogenic gene translocations occur in acute leukemia. So far no
structuralinformationforABL2hasbeenreported.Toelucidatestructuraldeterminantsforinhibitorinteraction,wedeterminedthe
cocrystalstructureofABL2withtheoncologydrugimatinib.Interestingly,imatinibnotonlyinteractedwiththeATPbindingsiteof
the inactive kinase but was also bound to the regulatory myristate binding site. This structure may therefore serve as a tool for the
development of allosteric ABL inhibitors. In addition, we determined the structures of ABL2 in complex with VX-680 and with an
ATP-mimetic type I inhibitor, which revealed an interesting position of the DFG motif intermediate between active and inactive
conformations, that may also serve as a template for future inhibitor design.
’INTRODUCTION
ABL2 (v-ABL Abelson murine leukemia viral oncogene
homologue 2), also known as ARG (ABL related gene), is a
member of the Abelson family of nonreceptor tyrosine kinases.
1 3
ABL2 and ABL1 (c-Abl) share a high degree of sequence
conservation and have a similar domain organization comprising
anN-terminal“cap”thatisimportantforautoinhibition,followed
by an SH3 SH2 kinase domain and a large C-terminal domain
containing docking sites for SH3 domains, F-actin, and micro-
tubules (Figure 1A).
3 The ABL kinases are ubiquitously ex-
pressed and regulate many cellular functions including re-
organization of the cytoskeleton, cell proliferation, adhesion,
andmigrationinresponsetostimulationofcellsurfacereceptors.
KnockoutmousestudieshaverevealedthatABL1andABL2play
overlapping roles and are required in development and T cell
function.
4,5 Despite their homology, ABL2 has a number of
distinctcellularfunctionsincludinganimportantroleinneurula-
tion, and it is required for adhesion-dependent neurite branch-
ing, synapse/dendrite stability, as well as ﬁbroblastic and
epithelial cell adhesion and migration.
Oncogenic forms of ABL are produced by retroviral transduc-
tion (v-Abl) or chromosomal translocation events. Fusion of the
ABL1 gene with the breakpoint cluster (BCR) gene gives rise to
an active, oncogenic tyrosine kinase BCR-ABL and is associated
with chronic myeloid leukemia (CML).
6,7 Other chimeric ABL
fusion gene products between ABL1 or ABL2 and ETV6 (ETS
translocation variant 6), also known as TEL (translocation ETS
leukemia), are associated with rare cases of CML and acute
myelogenous leukemia (AML).
8
Activity of ABL is regulated by an autoinhibitory mechanism,
andcellularactivityisnormallylow.Theinhibitorymechanismin
ABL diﬀers from that found in the closely related Src kinase
where interactions betweena phosphorylated tyrosine residuein
the C-terminal tail and the SH2 domain maintain the repressed
state of Src.
9 ABL kinases lack this critical tyrosine residue, and
the inactive conformation is maintained by an N-terminal
myristoyl group binding to a hydrophobic pocket in the kinase
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domain which places the SH2 SH3 domains on the large and
small lobes of the kinase, respectively, preventing its orientation
toanactivekinase.TwosplicevariantsofABL1exist(1aand1b)
that diﬀer only in their N-terminal region. ABL 1b is myristoy-
lated, whereas ABL 1a is not, and it has been suggested that
hydrophobic residues in the cap domain of ABL 1a may
functionally substitute for the myristate. The fusion of BCR, or
TEL, with ABL disrupts the autoinhibitory mechanism, and the
enhanced tyrosine kinase activity leads to leukemia.
Several inhibitors have been developed for the ABL kinases,
andthesearecurrentlyusedforthetreatmentofleukemiasuchas
CML. The most commonly used inhibitor imatinib mesylate
(STI571,CGP57148B)(Chart1)selectivelyinhibitsBCR-ABL,
ABL1,andABL2,aswellascertainotherkinasesincludingKIT,a
receptor tyrosine kinase that is a target of imatinib for treatment
of gastrointestinal stromal tumor.
10 12 Clinical trials with im-
atinibshowedthatmorethan90%ofCMLpatientsrespondedto
treatment;
13 however, a high percentage of patients in the
advanced phases of the disease developed resistance to the
treatment, mainly because of BCR-ABL mutants with no, or
reduced, sensitivity to imatinib inhibition.
14 16 This has led to
thedevelopmentofalternativeinhibitorssuchasdasatinib,which
is eﬀective against imatinib-resistant BCR-ABL mutants.
17 Un-
fortunately,theseinhibitorsarenoteﬀectiveagainstthecommon
BCR-ABL T315I mutation often found in relapsed CML
patients. The Aurora kinase inhibitors such as 1 (VX-680)
18
(Chart 1) and 3 (PHA-739358)
19 have considerable antitumor
activity, and 3 inhibits imatinib-resistant BCR-ABL mutations
includingT315I.
20Anewapproachinvolvingallostericinhibitors
thatbindtothemyristatebindingpockethaspotential:Grayand
colleagues recently reported the inhibitors GNF-2 and GNF-5
that bind in the myristate binding pocket and, when used
together with ATP-competitive inhibitors, can be used to over-
come resistance to ATP-site inhibitors.
21
Crystal structures have been solved for ABL1 in complex with
several inhibitors including imatinib,
22 dasatinib,
23 1,
24 and 3
25
that explain the observed potency proﬁles of these inhibitors
based on the structural conformations of the protein inhibitor
complexes. Recently, the structure of ABL1 with GNF-2 bound
was reported.
21
Here we present three structures of ABL2 kinase domain,
in complex with the inhibitors imatinib, 1, and 5-amino-3-((4-
(aminosulfonyl)phenyl)amino)-N-(2,6-diﬂuorophenyl)-1H-1,2,
4-triazole-1-carbothioamide 2 (JNJ-7706621) (Chart 1), a
1-acyl-1H-[1,2,4]triazole-3,5-diamine analogue thathasbeen
reported as a potent antitumor cyclin-dependent kinase
inhibitor.
26 The cocrystallized compound 2 bound to an inactive
ABL2 conformation that can be considered as an intermediate
between the canonical active DFG Asp in and inactive DFG Asp
out conformations. This conformation places the DFG pheny-
lanaline into the ATP site, providing the potential of aromatic
stacking interactions with inhibitors.
’RESULTS
Structural Comparison of ABL2 and ABL1. We initiated
structural studies on multiple constructs of ABL2 using baculo-
virus-mediated expression in insect cells. A construct spanning
residues 279 546 (Figure 1A), encompassing the kinase do-
main, gave high levels of soluble protein expression in Hi5 cells,
and purification yielded protein of suitable purity for crystal-
lization.ThreecrystalstructuresofthekinasedomainofABL2in
complex with 1, imatinib, and 2 (Figure 1B) were determined at
2.05, 1.65, and 2.81 Å resolution, respectively. All structures are
of the unphosphorylated form of ABL2. The overall structure of
the kinase domain in each of the structures is similar, with the
typical structural features of a protein kinase: the kinase domain
is made up of two lobes. The N-terminal lobe is the smaller
subdomain, composed of a five-stranded β-sheet and a promi-
nent R-helix. The larger C-terminal lobe consisting of residues
367 546 is mostly helical. Connecting the two lobes is a linker
that acts as a hinge about which the two lobes can rotate with
Figure 1. Structural comparison of ABL2 and ABL1. (A) Domain organization of ABL2, showing residue numbering and the percentage sequence
identity to ABL1 for each domain. (B) Ribbon diagram of the structure of ABL2 in complex with the type I inhibitor 2 to show the orientation of the
molecule underneath the surface depicted in (C). (Figure 5 shows this interaction in more detail.) (C) Two views of the surface representation of the
ABL2structureare shown,separatedbyarotationof180 .Residuesthatareconserved withABL1areshownasgraysurface,semiconservedresidues as
yellowsurface,andresiduediﬀerencesasredsurface.TheresiduediﬀerencesarenumberedinblackforABL2,andtheresiduelettersinredcorrespondto
their counterparts in ABL1. The representation on the left is the same orientation as in (B).2361 dx.doi.org/10.1021/jm101506n |J. Med. Chem. 2011, 54, 2359–2367
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respecttoeachotheruponATPandsubstratebinding.TheATP-
bindingsiteislocatedinapocketbetweenthetwolobes.ABL2is
93% identical to ABL1 over the kinase domain (Figure 1A), and
the residue differences are all surface-exposed (Figure 1C).
Interestingly,thehingeresidueT319inABL1isaprolineresidue
(P365) in ABL2 which may influence the interaction of ATP
mimetic inhibitors with the hinge backbone.
Structures of ABL2 in Complex with Imatinib and 1. The
structures of the ABL2 kinase domain in complex with imatinib
and 1 were determined to confirm the anticipated binding
arrangement based on the ABL1:imatinib or ABL1:1 structures.
As expected given the sequence similarity between ABL2 and
ABL1,thebindingofbothmoleculesintheATP-bindingsitewas
essentially identical to the equivalent ABL1 structure.
Compound 1 is bound with the N-methylpiperazine group
extending out of the ATP pocket, and the cyclopropane group
bound just past the gatekeeper residue Thr361 to form hydro-
phobic packing interactions with the methyl of Thr361 and the
side chain of Met336 (Figure 2A). As with ABL1,
24 1 binds to
ABL2 such that the activation segment is in an almost active
conformation,withtheAspoftheDFGmotifpointing“in”tothe
ATP binding site. Also as in ABL1:1 (and ABL1:imatinib), the
P-loop has a distorted conformation to allow the side chain of
Tyr299 to form an aromatic π-stacking interaction with the
inhibitor, although theinteraction involveslessofTyr299thanis
the case in ABL1:imatinib where the aromatic ring of Tyr299
packsperpendicularly tothepyridine aminopyrimidinerings of
imatinib. The ABL1:1 complex was of the imatinib-resistant
mutant of ABL1, H396P, which is a mutation in the activation
segment; however, the conformation of the wild-type ABL2:1
(also His at this position) was identical in this region. This
observation provides additional conformation that the H396P
mutation hinders formation of the inactive (DFG Asp out)
conformation recognized by imatinib, without altering the active
activation segment conformation recognized by 1.
While ABL2:1 was as anticipated, the structure of ABL2:
imatinib showed an unexpected result: two imatinib molecules
were found bound to ABL2, one in the active site (ATP binding
site) of the kinase (Figure 2A) and the other at a remote site
equivalent to the myristate binding site (Figure 4). Isothermal
titration calorimetry (ITC) with ABL2 and imatinib was carried
out to determine whether both binding sites are occupied in
solution. The ITC data support a model with two molecules of
imatinib bound to the ABL2 construct, with dissociation con-
stants (KD) of 6 nM and 0.5 μM (Figure 3).
Chart 1. Chemical Structures of Imatinib, 1, and 2
Figure 2. Comparison of ABL2:imatinib and ABL2:1 with ABL1:
imatinib and ABL1:1. (A) Imatinib bound in the active sites of ABL1
and ABL2. The structure of the active site of ABL1 with imatinib bound
(blue) (PDB code 1IEP)
22 is shown superimposed on ABL2:imatinib
(orange), showing that the inhibitor molecules bind in the same
conformation in both structures. Imatinib is shown in yellow for
ABL2 and green for ABL1. (B) 1 bound in the active sites of ABL1
and ABL2. The structure of the active site of ABL1 with 1 bound (PDB
code 2F4J)
24 is shown superimposed on ABL2:1. Coloring is as for (A)
except that 1 is in yellow for ABL2 and purple for ABL1.2362 dx.doi.org/10.1021/jm101506n |J. Med. Chem. 2011, 54, 2359–2367
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Themoleculeofimatinibboundtotheactivesiteisinthesame
conformation as reported for the imatinib:ABL1 complex (PDB
code 1IEP) (Figure 2A), and the structures were superimposed
with an rmsd of 0.61 Å over 258 CR atoms. Hydrogen-bonding
interactionswiththeactivesiteresiduesareconserved(Table1).
AsinthecaseofABL1,
27imatinibrecognizedtheinactive,“DFG
out”, conformation of ABL2 with the activation segment in a
similar inhibitory conformation, although partly disordered.
Asp381 of the DFG motif (equivalent to Asp427 in ABL1) is
pointing away from the ATP binding site, whereas Phe382
(ABL1:Phe428) is pointing toward the ATP binding site and
forming an aromatic stacking interaction with the inhibitor. The
gatekeeper residue Thr361 (ABL1:Thr315) and Glu332 (ABL1:
Glu286) from RC form hydrogen bonds to imatinib (Figure 2A,
Table 1).
The second imatinib molecule in ABL2 bound in an extended
conformation in the myristate binding pocket (Figure 4A) and
forms a hydrogen bond with the carbonyl group of Ala383 on helix
RE. Superimposition of the ABL1/myristic acid complex (PDB
code 1OPL) with ABL2:imatinib (Figure 4B) shows how imatinib
mimics myristic acid binding. The superimposition with the
C-terminally extended ABL1 structure shows how our shorter
ABL2 construct (residues 279 546, numbering from isoform B)
usedforcrystallizationpermittedthebindingofimatinibatthissite;
however, the full length protein (with the ABL1 or ABL2
C-terminus) would be unlikely to bind imatinib at this position
because of a steric clash with the RI0 helix, which was omitted from
ourconstruct.Withtheshorterconstruct,Phe543pointsawayfrom
the myristic acid binding pocket, also avoiding a steric clash that
would occur in the full-length protein, as can be seen from the
conformation of ABL1 Phe516 (Figure 4B). If binding did occur
between imatinib and full-length ABL1 or ABL2 at the myristate
binding pocket, it would not be accompanied by the bending of
helix RI0 that is necessary for inhibition.
28 Apart from the shorter
constructusedforABL2,therearenosequencediﬀerencesbetween
ABL1 and ABL2 in the region of the myristic acid binding pocket,
andtheresultshereforABL2presumablywouldapplyalsotoABL1
given a similar construct.
StructureofABL2inComplexwith2.ThestructureofABL2
kinasedomainincomplexwith2
26wasdeterminedtoinvestigate
the binding mode of this inhibitor. Compound 2 is a potent,
ATP-competitive type I inhibitor, targeting CDK1/CDK2,
which shows significant antitumor activity.
26 The structure of
ABL2:2 superimposes with ABL2:imatinib with an rmsd of 1.05
Å over 238 CR atoms. Compound 2 binds to the ATP binding
Figure3. Isothermaltitrationcalorimetry(ITC)ofABL2andimatinib.
The data show that ABL2 binds imatinib at two sites.
Figure 4. Myristate binding pocket of ABL2. (A) Surface of the
myristate binding pocket of ABL2, with imatinib shown as a yellow
ball-and-stick representation. (B) Overlay of the ABL1:myristic acid
complex (PDB code 1OPL) (orange and black) and ABL2:imatinib
(blue and yellow) structures at the myristate binding site. Phe516
(ABL1)andPhe543(ABL2)areshowninorangeandblue,respectively.
Residues516,521,and525ofABL1,fromthebentRI0 helix,occupypart
of the space occupied by imatinib in the ABL2 structure. These residues
werenotpresentintheABL2constructusedtodeterminethestructure.
Table 1. Comparison of Hydrogen Bond Distances to Im-
atinib from ABL and ABL2
ABL ABL2
a
N51 Ile360 O = 2.7 Å N51 Ile406 O = 2.8 Å
N51 His361 O = 3.1 Å N51 His407 O = 3.2 Å
O29 Asp381 N = 3.0 Å O29 Asp427 N = 2.8 Å
N21 Glu286 OE2 = 3.1 Å N21 Glu332 OE2 = 3.0 Å
N13 Thr315 OG1 = 3.0 Å N13 Thr361 OG1 = 3.1 Å
N3 Met318 N = 2.9 Å N3 Met364 N = 2.9 Å
aThe ABL2 numbering refers to ABL2 isoform B (gi|6382062).2363 dx.doi.org/10.1021/jm101506n |J. Med. Chem. 2011, 54, 2359–2367
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site, with the aminothiazole moiety occupying the adenine
binding site (Figure 5A). The ligand is bound to the protein by
hydrogen bonds to the backbone carbonyls of residues Glu362
and Met364 in the hinge region, in common with many ATP-
mimetic inhibitors, as well as an aromatic aromatic ring inter-
actionwithTyr299fromtheP-loop,whichisorientedtowardthe
activesite(Figure5A).Theconformationof2isalmostidentical
to that observed in the various other structures of kinases in
complex with this ligand in the PDB (discussed below).
InABL2:2theactivationloopisfullyorderedinan“activated”
conformation, which can be seen from a comparison with the
structure of ABL1:ADP (PDB code 2G2I)
29 (Figure 5D,E); the
activation segment is well ordered and is stabilized by a salt
bridge between Arg432 and the RC glutamate (Glu338) as well
asastackinginteractionbetweentheactivationsegment tyrosine
(Tyr439) and the catalytic HRD motif arginine (Arg408).
Compared to the structure of ABL2:imatinib, the loop region
N-terminal to RC of ABL2:2 is in a signiﬁcantly diﬀerent
conformation (Figure 5C,D), although this may be inﬂuenced
by crystal packing interactions. Helix RC itself is correctly
oriented as indicated by the presence of the salt bridge between
the active site lysine residue Lys317 and the RC glutamate
residue Glu332. However, the helix does not bend inward as in
the ABL1:ADP structure (Figure 5E), where the lack of a bound
inhibitor allows the hydrophobic pocket formed by Ile313,
Thr315, and Met290 (ABL1 numbering) to shrink, pulling the
middle of helix RC toward the ATP binding site.
The most unusual feature of the ABL2:2 structure is the
arrangement of the DFG motif. Typically in an inactive (DFG
Asp out) conformation such as that in ABL2:imatinib
(Figure 5C), the Asp from the DFG motif is “out”, pointing
away from the ATP binding site, while the Phe points into the
binding site. In many complexes of kinases with inhibitors the
Phe interacts with a hydrophobic part of the inhibitor molecule.
In an active conformation the backbone rotates to allow the Asp
to point “in” and coordinate the Mg
2þ. However, in ABL2:2,
while the backbone conformation of the DFGmotifis in the Asp
“out”conformation,thePhesidechainisrotated120 upintothe
hydrophobic pocket adjacent to the ATP binding site. A com-
parison of ABL2:2 with the structure of ABL1 in complex with
PD166326(PDBcode1OPK),
30aninhibitorofsimilarchemical
structure,showsthatintherotatedpositionPhe428occupiesthe
position of the dichlorophenyl ring of the larger inhibitor in
ABL1:PD166326 (Figure 5A,B). In this position it binds in the
hydrophobic pocket formed by Ile359, Thr361, Met336, and
Lys317. It is presumably for this reason that ABL2:2 does not
have the bent RC conformation observed in ABL1:ADP
(Figure 5E), despite also having a smaller molecule bound to
the ATP binding site.
’DISCUSSION
The overall structure and binding mode of the inhibitors
imatinib and 1 is conserved between ABL1 and ABL2; however,
Figure 5. ABL2 bound to a type I inhibitor 2. (A) ABL2:2, showing the compound bound to the ATP binding site, and the ordered activation loop.
Compound 2 is shown in yellow. The DFG motif is shown in green, and the hydrophobic pocket in which the DFG Phe binds is shown in brown. (B)
ABL1:PD166326 (PDB code 1OPK),
30 showing PD166326 in purple. Other coloring is as in (A). This shows the dichlorophenyl group of PD166325
occupyingthesamevolumeastheDFGPhesidechainin(A).(C)ABL2:imatinib.(D)ABL2:2fromadiﬀerentangletoshowclearlytherotationofthe
DFG motif and the intermediate position of the DFG Phe residue relative to (C) and (E). (E) ABL1:ADP (PDB code 2G2I).
292364 dx.doi.org/10.1021/jm101506n |J. Med. Chem. 2011, 54, 2359–2367
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thediscoverythatinatruncatedconstructofABL2,imatinibalso
binds in the myristate binding pocket represents an important
and novel ﬁnding in light of the recent interest in developing
allosteric modulators of this site such as GNF-2 (3-[6-[[4-
triﬂuoromethoxy)phenyl]amino]-4-pyrimidinyl]benzamide)
31
which binds in the myristate binding pocket, as recently con-
ﬁrmed by a cocrystal structure.
21 It is clear from the ABL2:
imatinib structure that in the full-length protein imatinib would
notbindinthemyristatebindingpocketinsuchawaythatwould
cause inhibition by promoting the bending of helix RI0 and the
dockingoftheSH2andSH3domains,
28duetoastericclashwith
a bent helix RI0. However, a truncated imatinib molecule
presumably would bind in this context and may oﬀer a starting
point for the design of alternative allosteric ABL inhibitors.
The linear region of imatinib (excluding the pyridine 
aminopyrimidine rings) is colinear with the binding position of
myristate (Figure 4B) and therefore represents a useful template
fragment. Such allosteric inhibitors are potentially valuable for
overcoming the resistance of various mutant ABL proteins to
ATP-mimetic inhibitors, and it has recently been shown that it is
also possible to target this pocket for activation of ABL if the
molecule binds but does not induce a bending of helix RI.
28
Therefore, molecules that are developed to bind in this pocket
wouldneedcharacterizationofantagonistversusagonistactivity.
We have previously crystallized the type I inhibitor 2 with a
number of other human protein kinases. In all of these other
structures a rotated DFG motif Phe was not observed, and all
showed a typical DFG Asp “out” conformation. The distinguish-
ing feature in ABL2 that makes the unusual Phe conformation
possible is the larger volume between the Thr361 gatekeeper
residue Lys317 (from the salt bridge to RC) and the other
residues of the hydrophobic pocket (Figure 5). All of the other
kinases we have crystallized with 2 have a larger, hydrophobic
gatekeeper residue, for example, CSNK1G3 (casein kinase 1 γ3,
PDB code 2CHL, leucine gatekeeper), SLK (Ste20-like kinase,
PDB code 2J51, Ile gatekeeper),
32 CAMK4 (PDB code 2W4O,
leucine gatekeeper), and CLK3 (CDC-like kinase 3, PDB code
2WU6, Phe gatekeeper),
33 and also a generally smaller hydro-
phobic pocket. For example, ABL2 has a distance of 9.2 Å
between its gatekeeper CR backbone atom and Lys317 CR
backbone atom, while CSNK1G3, SLK, CAMK4, and CLK3
have distances of 7.8, 8.1, 7.5, and 8.9 Å, respectively. The
combination of the larger side chains and the smaller CR CR
distancesmeansthatintheseotherstructuresthereisnotenough
space for the DFG Phe side chain to bind in the same hydro-
phobic pocket. Compared to these other structures, ABL2 and
ABL1 have more space that allows the rotation of Phe428. All of
thestructurespresentedherehaveahydrophobicentityboundin
thisposition:intheimatinibcomplexitisanaromaticring;inthe
compound 1 complex it is the cyclopropane ring; and in the
compound 2 complex, it is the side chain of Phe428.
TheABL2:2structuresuggestsitispossiblethatPhe428could
exist in this rotated “intermediate in/out” position even in the
presence of the imatinib-resistant gatekeeper mutation T315I
(ABL1 numbering) (Figure 5A and Figure 5D), and it may be
thatthisconformationofthekinasecouldbetargetedforsecond-
line treatment following imatinib resistance, especially since it is
also compatible with the ordered activation loop seen with the
alternativeimatinib-resistantactivationloopmutationH396P.In
the same way that 1 successfully targets gatekeeper mutations by
allowing suﬃcient space around the gatekeeper residue by its
“Y”-shape (compare Figure 2A and Figure 2B) and its small
cyclopropaneringboundinthehydrophobicpocket,thisPhe428
conformation might also be compatible with a mutated gate-
keeperresidue.IndeedasuperimpositionofABL2:1andABL2:2
showsthatthePhe428-boundconformationactuallyallowsmore
space around the gatekeeper than 1 (data not shown). Thus,
targeting this conformation may also provide additional oppor-
tunities for achieving inhibitor speciﬁcity.
’MATERIALS AND METHODS
Cloning of ABL2 Kinase Domain. Residues 279 546 of the
kinasedomainofhumanABL2(gi|6382062,Argtyrosinekinaseisoform
B) were cloned into a pFastBac-derived transfer vector in-frame with an
N-terminal hexahistidine tag and TEV protease cleavage site. This
plasmid was transformed into Escherichia coli strain DH10Bac which
contains bacmid DNA. Therecombinant bacmid DNA was isolated and
verifiedbyPCR.Inordertogeneratethebaculoviruses,therecombinant
bacmidDNAwasusedfortransfectionofSf9insectcellsfollowedbytwo
rounds of amplification in Sf9 cells.
Protein Expression and Purification of ABL2 Kinase Do-
main. For expression of the protein, baculovirus obtained from the Sf9
cell culture was used to infect Trichoplusia ni (Hi5) cells grown in
suspension to a density of 2   10
6 cells/mL. At 48 h postinfection the
cells were harvested by centrifugation and cell pellets were stored at
 80  C. Cells were resuspended in a buffer consisting of 5 mM
imidazole, 500 mM NaCl, 50 mM Hepes, pH 7.4, 5% glycerol,
0.5 mM tris(2-carboxyethyl)phosphine (TCEP), supplemented with
complete protease inhibitor mixture (Roche Applied Sciences), and
lysedbysonication.Thelysatewascentrifugedat45000gfor1hat4 C.
The supernatant was filtered and loaded onto nickel-chelating resin.
After being washed, the protein was eluted with the above buffer plus
50 300 mM imidazole and the eluates were combined. The hexahis-
tidine tag was removed by overnight treatment with TEV protease at
4 C.ThedigestedABL2wasconcentratedto2.5mLvolumeandloaded
onto a Superdex75 gel filtration column (HiLoad 16/60, GE
Healthcare) equilibrated in 10 mM Hepes, pH 8.0, 300 mM NaCl,
and 0.5 mM TCEP.
The protein identity was veriﬁed by electrospray ionization time-of-
ﬂight mass spectrometry (Agilent LC/MSD). Prior to removal of the
hexahistidine tag, the observed mass was 33414 Da compared to a
calculated mass of 33502; it is likely that the diﬀerence in mass was due
to removal of the N-terminal methionine followed by acetylation. After
removal of the hexahistidine tag the observed mass was 30980 Da,
matching exactly the calculated mass.
Crystallization and Data Collection. The ABL2:imatinib com-
plex(PDBcode3GVU,Table2)wascrystallizedat4 Cin200nLdrops
from a 1:1 ratio of ABL2:imatinib (4 mg/mL protein containing 1 mM
imatinib) and reservoir solution (20% PEG3350, 0.1 M citrate, pH 5.5).
The crystals were then cryoprotected in reservoir solution with 20% (v/v)
PEG300 and flash-frozen in liquid nitrogen. X-ray diffraction data was
collected at 100 K on beamline X10SA at the Swiss Light Source (SLS).
The ABL2:2 complex (PDB code 3HMI) was crystallized at 4  Ci n
200 nL drops from a 3:1 ratio of ABL2:2 (8 mg/mL protein containing
1 mM compound 2 (5-amino-3-((4-(aminosulfonyl)phenyl)amino)-
N-(2,6-diﬂuorophenyl)-1H-1,2,4-triazole-1-carbothioamide, Calbio-
chemproductno.217714)andreservoirsolution(0.1Mlithiumsulfate,
0.05 M disodium hydrogen phosphate, 0.05 M citric acid, 19% (v/v)
PEG1000). The crystals were cryoprotected in reservoir solution with
25% (v/v) ethylene glycol and ﬂash-frozen in liquid nitrogen. X-ray
diﬀraction data was collected at 100 K on beamline I03 at DIAMOND.
The ABL2:1 complex (PDB code 2XYN) was crystallized at 4  Ci n
200nLdropsfroma2:1ratioofABL2:2(10mg/mLproteincontaining
1m M1 (GSK487830B)) and reservoir solution (0.8 M sodium
succinate). The crystals were cryoprotected in reservoir solution with2365 dx.doi.org/10.1021/jm101506n |J. Med. Chem. 2011, 54, 2359–2367
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25% (v/v) glycerol and ﬂash-frozen in liquid nitrogen. X-ray diﬀraction
data was collected at 100 K on beamline I03 at DIAMOND.
Structure Determination and Refinement. The diffraction
imageswereprocessedusingMOSFLM
34andSCALAintheCCP4suite
of programs.
35 Structures were solved by molecular replacement using
Phaser
36 with ABL1 as a search model and were refined against
maximum likelihood targets using restrained refinement and TLS
parameters (where appropriate), as implemented in the program
REFMAC.
37 Iterative rounds of refinement were interspersed with
manual rebuilding of the models using COOT.
38 Progress of the
refinement for each structure was judged throughout by following a
reduction in Rfree (calculated from a random 5% of the data that was
excluded from the refinement).
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